Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05123001 · ClinicalTrials.gov registry record
Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse Events
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 11
- Enrollment target
NCT05123001: Completed study, sponsored by Stanford University.
NCT05123001 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05123001 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to monitor physiological and molecular changes during and following CAR-T cancer cell therapy, towards improved management of adverse events including Cytokine Release Syndrome and neurotoxicity. Our study aims are to improved early detection and precise management of adverse events for patients receiving Chimeric antigen receptor T- cell (CAR-T): 1. To assess the feasibility, including accuracy, usability, and usefulness of wearable sensors in CAR-T patients. 2. To generate comprehensive multiomic profile analysis following CAR-T therapy. 3. To perform integrated analysis of wearables sensor data, omics data, and symptom/clinical data.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2021-07-15 |
| Est. Completion | 2022-07-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05123001
The ClinicalTrials.gov registry entry for NCT05123001 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05123001 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05123001 about?
NCT05123001 is a clinical study titled "Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse Events". The purpose of this study is to monitor physiological and molecular changes during and following CAR-T cancer cell therapy, towards improved management of adverse events including Cytokine Release Syndrome and neurotoxicity. Our study aims are to improved early detection and precise management of a...
What is the current status of trial NCT05123001?
This trial is currently completed. The enrollment target is 11 participants. The study started on 2021-07-15. Estimated completion is 2022-07-07.
Who is sponsoring clinical trial NCT05123001?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.